UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the
Securities Exchange Act of 1934
Date of Report (Date of earliest event reported): June 29, 2016
TESARO, Inc.
(Exact name of registrant as specified in its charter)
Delaware (state or other jurisdiction of
incorporation) | | 001-35587 (Commission
File Number) | | 27-2249687 (I.R.S. Employer
Identification No.) |
1000 Winter Street
Suite 3300
Waltham, Massachusetts | | 02451 |
(Address of principal executive offices) | | (Zip Code) |
Registrant’s telephone number, including area code: (339) 970-0900
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):
o Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
o Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
o Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
o Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
Section 8 — Other Events
Item 8.01 Other Events.
On June 29, 2016, TESARO, Inc. (the “Company”) issued a press release announcing positive top-line results from a Phase 3 clinical trial of niraparib, an orally active and potent poly (ADP-ribose) polymerase, or PARP, inhibitor, for the treatment of patients with high grade serous, platinum sensitive, relapsed ovarian cancer, which the Company refers to as the NOVA trial. A copy of the press release announcing these results is attached to this Current Report on Form 8-K as Exhibit 99.1 and incorporated herein by reference.
Section 9 — Financial Statements and Exhibits
Item 9.01 Financial Statements and Exhibits.
(d) Exhibits.
Exhibit No. | | Description |
| | |
99.1 | | TESARO, Inc. press release dated June 29, 2016 |
2
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
| TESARO, Inc. |
| |
| |
| By: | /s/ Joseph L. Farmer |
| | Joseph L. Farmer |
| | Senior Vice President, General Counsel and Secretary |
Dated: June 29, 2016
3
EXHIBIT INDEX
Exhibit No. | | Description |
| | |
99.1 | | TESARO, Inc. press release dated June 29, 2016 |
4
